• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

    11/13/24 5:35:29 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TENX alert in real time by email
    SC 13G/A 1 tenx13ga1.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

     

    Tenax Therapeutics, Inc.

    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

     

    88032L605

    (CUSIP Number)

     

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 88032L605

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 372,797

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 372,797

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 372,797

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. 88032L605

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 372,797

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 372,797

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 372,797

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) PN

     

     3 
    CUSIP No. 88032L605
    1.Names of Reporting Persons.

    Stonepine GP, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 372,797

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 372,797

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 372,797

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) OO

     

     4 
    CUSIP No. 88032L605

     

    1.Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 372,797

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 372,797

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 372,797

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 9.99%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     5 
    CUSIP No. 88032L605

     

    Item 1.

     

    (a)Name of Issuer

    Tenax Therapeutics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:


    Stonepine Capital Management, LLC, a Delaware limited liability company (“Stonepine”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Stonepine GP, LLC, a Delaware limited liability company (the “General Partner”)

     

    Jon M. Plexico (collectively, the “Filers”)

     

    Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, $0.0001 par value per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 88032L605
     6 
    CUSIP No. 88032L605
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to Stonepine and the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The shares of Common Stock beneficially owned by the Filers reported in this Schedule 13G consist of (1) 50,000 shares of Common Stock, (2) Prefunded Warrants to acquire 950,000 shares of Common Stock, and (3) Warrants to acquire 500,000 shares of Common Stock. The Prefunded Warrants and the Warrants are each subject to a 9.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 3,408,906 shares of Common Stock outstanding as of August 10, 2024, as reported in the Form 10-Q filed by the Issuer on August 13, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of Stonepine, the General Partner and Mr. Plexico

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. 88032L605

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 13, 2024

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine GP, LLC,
    General Partner

    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     

    STONEPINE GP, LLC


    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

       

     

     8 
    CUSIP No. 88032L605

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: October 10, 2024

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine GP, LLC,
    General Partner

    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     

    STONEPINE GP, LLC


    By: /s/ Jon M. Plexico
    Jon M. Plexico
    Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     

     

     

     

     

    Get the next $TENX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TENX

    DatePrice TargetRatingAnalyst
    10/24/2024$16.00Outperform
    Leerink Partners
    10/14/2024$16.00Buy
    Guggenheim
    9/30/2024Outperform
    William Blair
    More analyst ratings

    $TENX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

      CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025. Details of presentation: Format: Corporate Presentation Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer, Doug Randall, Chief Business Officer Date and Time: April 7, 2025, at 3:45 p.m. ET The live and archived webcast of

      3/31/25 8:00:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 Phase 3 LEVEL Study Expansion Increases Statistical Power; Enrollment Completion Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies,

      3/25/25 4:05:00 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Announces $25 Million Private Placement

      CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting placement agent fees and other private placement expenses. The private placement will be for an aggregate of 378,346 shares of the Company's common stock and pre-funded warrants to purchase an aggrega

      3/5/25 8:47:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Financials

    Live finance-specific insights

    See more
    • Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

      Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. "Having completed the merger with PHPrecisionMed Inc., we now have product development programs in group one and group two pulmonary hypertension patients," stated Anthony DiTonno, Chief Executive Officer of Tenax, "which represent more than 70% of the overall market. "We have begun the open label transition study using the oral formulation of Levosimendan, which was recently acq

      5/17/21 5:15:00 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

      MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition expands Tenax’s pulmonary hypertension pipeline with the addition of imatinib, a Phase 3 ready candidate. Imatinib is a tyrosine kinase i

      1/19/21 7:45:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Tenax Therapeutics Inc.

      DEFA14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

      4/25/25 7:45:16 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Tenax Therapeutics Inc.

      DEF 14A - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

      4/25/25 7:42:43 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Tenax Therapeutics Inc.

      EFFECT - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

      4/24/25 12:15:09 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tenax Therapeutics Inc.

      SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/14/24 7:14:21 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

      SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/14/24 12:21:05 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

      SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/13/24 5:35:29 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TENX
    Leadership Updates

    Live Leadership Updates

    See more

    $TENX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TENX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TENX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

      CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Ms. Andor will lead the Company's expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). "We are

      1/22/25 8:00:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board

      CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company's PH-HFpEF Scientific Advisory Board (SAB). "We are thrilled to welcome Dr. Butler to our Scientific Advisory Board," said Stuart Rich, M.D., Chief Medical Officer of Tenax Therapeutics. "Javed is regarded as one of the most eminent clinical trialists in cardiovascular medicine, and he joins three highly distinguished cardiovascular lead

      11/17/23 8:30:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by no longer 10% owner Dellora Investments Lp

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      3/12/25 5:26:30 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Dellora Investments Lp claimed ownership of 351,071 shares (SEC Form 3)

      3 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      1/10/25 4:27:18 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Rich Stuart

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      12/12/24 8:09:56 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Tenax Therapeutics with a new price target

      Leerink Partners initiated coverage of Tenax Therapeutics with a rating of Outperform and set a new price target of $16.00

      10/24/24 6:39:21 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Tenax Therapeutics with a new price target

      Guggenheim initiated coverage of Tenax Therapeutics with a rating of Buy and set a new price target of $16.00

      10/14/24 7:43:13 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Tenax Therapeutics

      William Blair initiated coverage of Tenax Therapeutics with a rating of Outperform

      9/30/24 7:51:49 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Proehl Gerald T bought 1,666 shares, increasing direct ownership by 166,600% to 1,667 units (SEC Form 4)

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      8/8/24 7:43:25 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Davidson Michael H. bought 2,500 shares, increasing direct ownership by 656% to 2,881 units (SEC Form 4)

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      8/8/24 7:42:23 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care